All News
ACR Urges Congress to Prioritize Medicare Pay Cuts, Prior Authorization, and Telehealth
As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R.
Read Article
Xeljanz Cancer Risks Detailed
d
MedPage Today
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
Read Article
Oligoarticular PsA: FOREMOST Study
Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study
https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk
Links:
Dr. John Cush RheumNow ( View Tweet)
Sensor-engineered glove evaluates hand function in RA
Dr. David Liew discusses abstract 0904 at ACR22 Convergence. Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis
https://t.co/e5VCOC56BC https://t.co/vfuVWMrqSj
Links:
Dr. John Cush RheumNow ( View Tweet)
Netherlands study of 220 consecutive inflammatory arthritis pts enrolled in electronic remote telehealth monitoring showed that 141 (64%) dropped out, with a median dropout at 17 wks ( moreso in women). Why? Simple is not alway simple... https://t.co/nziKil4vas https://t.co/oyyulMnIu1
Links:
Dr. John Cush RheumNow ( View Tweet)
National cohort of 20–39-yr old men - among ~1.3 million, 18,473 Dx w/ gout (incidence 3.36/1,000 PY). Developing metabolic syndr doubled #gout risk (aHR 2.31); MetS at all visits had 4x risk (aHR 3.82) & MetS recovery reduced gout risk by 59% https://t.co/bLmf1AL5VI https://t.co/8c47zk6vqu
Links:
Dr. John Cush RheumNow ( View Tweet)
Top 10 Pharma Revenues 2021:
1 J&J $93.77 billion (USD)
2 Pfizer $81.29 B
3 Roche $68.7 B
4 AbbVie S$56.2 B
5 Novartis $51.63 B
6 Merck $48.7 B
7 BMS $46.4 B
8 GSK $43.57 B
9. Sanofi $44.67 B
10. AstraZeneca $37.47 B
https://t.co/ptFAyk4S5S https://t.co/cCtPboI53x
Links:
Dr. John Cush RheumNow ( View Tweet)
Goofy or Novel: "How gravity may cause irritable bowel syndrome". A hypothesis, published in the American Journal of Gastroenterology, describes how the intestines, spine, heart, nerves and brain evolved to manage gravity. https://t.co/lLyAkruyyy? https://t.co/TJH8Du8rm6
Links:
Dr. John Cush RheumNow ( View Tweet)
Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines
Following the 2016 American Academy of Ophthalmology Guidelines, rheums have dutifully reduced the dose of HCQ taken by patients with SLE to some number south of 5mg/kg per day.
https://t.co/iToRttwPbC https://t.co/REpWkI7vC0
Links:
Dr. John Cush RheumNow ( View Tweet)
A Multidimensional Approach in the Management of Axial Spondylarthritis
Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis.
https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo
Links:
Dr. John Cush RheumNow ( View Tweet)
Visit our podcast channel and listen to experts from the #SLEEducatorsNetwork discuss how biologic therapies could help address key unmet needs in #lupus, and how clinicians can identify the most appropriate patients for biologics.
#SponsoredbyGSKUSMA
https://t.co/zYB48YvNDC https://t.co/gL67G5jQv8
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/zFsPUdo4Wb https://t.co/rEN4yfoP9h
Links:
Dr. John Cush RheumNow ( View Tweet)
Sparks editorial -- RA pathogenesis has been linked to pollution, Lung Dz, smoking, silica dust, asbestos, textile dust, brick/concrete laying, pesticides, military burn pits - some w/ strong associ w/ HLA-SE and ACPA, but not ACPA-negative RA https://t.co/ZStmF8MeLD https://t.co/xQxJ74aQ81
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE: Variability in Racial Disparities in Pregnancy Outcomes
Significant disparities exist in pregnancy outcomes in women with SLE, w/previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women w/SLE.
https://t.co/1PrJYpMcHx https://t.co/YN7K0Gf5Jl
Links:
Dr. John Cush RheumNow ( View Tweet)
Tapering Methotrexate with Biologics or JAK Inhibitors in RA
Dr Segan ( @JulianSegan) discusses Abstract 0916 at #ACR22.
https://t.co/CUjZ7SiSoE https://t.co/VYtmCIJEt6
Links:
Dr. John Cush RheumNow ( View Tweet)
Lifestyle Modifications may enhance TNF Inhibitors in axSpA
https://t.co/0O4jd3g0WL https://t.co/zUaRUR9tGL
Links:
Dr. John Cush RheumNow ( View Tweet)
The Top 10 Research Priorities in Psoriatic Arthritis
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
https://t.co/zfivHvtLX9 https://t.co/LZsiE417w2
Links:
Dr. John Cush RheumNow ( View Tweet)
Multi-ancestry analysis reveals novel genetic loci associated with OA
https://t.co/AIo3il8uHP https://t.co/nXGtOCCZsA
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review comparing MIS-C and Kawasaki: 14 studies, 2928 pts; major differences- KD pts were younger; MIS-C had more Pulm, GI, Shock, more cardiac (LV, valvular pericarditis, myocarditis), but less coronary lesions & conjunctivitis https://t.co/bcCRh5HxL7 https://t.co/qLvfCYwx9u
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparing Biosimilar Growth in the US, Germany, and Switzerland
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
https://t.co/LYcG0BNO6C https://t.co/V2m8HoIWLF
Links:
Dr. John Cush RheumNow ( View Tweet)